Buscar en
Actas Urológicas Españolas (English Edition)
Toda la web
Inicio Actas Urológicas Españolas (English Edition) Association between late-onset hypogonadism syndrome plus metabolic syndrome and...
Journal Information
Vol. 40. Issue 7.
Pages 440-445 (September 2016)
Share
Share
Download PDF
More article options
ePub
Visits
3
Vol. 40. Issue 7.
Pages 440-445 (September 2016)
Original article
DOI: 10.1016/j.acuroe.2016.06.005
Association between late-onset hypogonadism syndrome plus metabolic syndrome and prostate cancer and its aggressiveness
Asociación del síndrome de hipogonadismo tardío y síndrome metabólico con el cáncer de próstata y su agresividad
Visits
...
J. Fuentes-Pastora,, P. Pellejerob,, I. Ortizc, M. Ramírez-Backhausd,
Corresponding author
ramirezfivo@gmail.com

Corresponding author.
, A. de Graciad, C. Marrugod, A. Gomez-Ferrerd, A. Calatravae, J. Rubio-Brionesd, C. Rodriguez-Torreblancac, E. Solsona-Narbónd
a Servicio de Urología, Hospital Universitario de Marqués de Valdecilla (HUMV), Santander, Spain
b Servicio de Urología, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain
c Departamento de Matemática Aplicada, Universidad de Almería, Almería, Spain
d Servicio de Urología, Fundación Instituto Valenciano de Oncología (IVO), Valencia, Spain
e Servicio de Anatomía Patológica, Fundación Instituto Valenciano de Oncología (IVO), Valencia, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Tables (3)
Table 1. Clinical data of patients under study.
Table 2. Association of the variables with PCa and clinically significant PCa.
Table 3. Summary of data in the different groups.
Show moreShow less
Abstract
Objective

To assess the relationship between prostate cancer (PC) and the presence of metabolic syndrome and late-onset hypogonadism (LOH) syndrome.

Material and method

A retrospective study was conducted on 686 patients who underwent prostate biopsy. We analyzed the demographic variables, clinical data and biopsy results. To diagnose metabolic syndrome, we employed the criteria of the American Heart Association. For the diagnosis of LOH syndrome, we employed the Androgen Deficiency in the Aging Male questionnaire and testosterone levels (TT). We evaluated the relationship between free testosterone (FT) and bioavailable testosterone (BT) on one hand and PC and its aggressiveness on the other, as well as the usefulness of the TT to prostate specific antigen (TT/PSA) ratio in the PC diagnosis.

Results

The patient's median age was 65 years. Metabolic syndrome is not associated with PC (39.4% vs. 35%; p=0.1) but is associated with a PC Gleason score>7 (50.4% vs. 29.44%; p=0.002). LOH, low FT and low BT are associated with an increased presence of PC (51% vs. 35%, p=0.02; 44.86% vs. 33.33%, p=0.03; and 46.46% vs. 33.08%, p=0.01, respectively) and with an increased probability of a PC Gleason score>7 (61.54% vs. 37.5%, p=0.02; 54.17% vs. 34.12%, p=0.02; 54.35% vs. 34.48%, p=0.02, respectively). Additionally, the median TT/PSA ratio was significantly lower in patients with positive biopsies (p=0.022).

Conclusions

Metabolic syndrome was not associated with the probability of having PC but was associated with a PC Gleason score>7. Moreover, LOH syndrome had a higher percentage of PC and a greater presence of PC Gleason score>7, as did low levels of FT and low levels of BT.

Keywords:
Prostate cancer
Late-onset hypogonadism syndrome
Metabolic syndrome
Resumen
Objetivo

Evaluar la relación entre el cáncer de próstata (CaP) y la presencia de síndrome metabólico (SM) y síndrome de hipogonadismo tardío (SHT).

Material y método

Estudio retrospectivo de 686 pacientes sometidos a biopsia prostática. Analizamos: variables demográficas, datos clínicos y resultados de la biopsia. Para diagnosticar el SM se utilizaron los criterios de la American Heart Association. Para el diagnóstico de SHT se utilizó el cuestionario ADAM y los niveles de testosterona (TT). Evaluamos la relación de la testosterona libre (TL) y testosterona biodisponible (TB) con el CaP y su agresividad y la utilidad de la ratio TT/PSA en el diagnóstico de CaP.

Resultados

Mediana de edad 65 años. El SM no se asoció al CaP (39,4% vs 35% p=0,1) pero sí a un CaP Gleason>7 (50,4% vs 29,44% p=0,002). El SHT, TL baja y TB baja se asociaron a una mayor presencia de CaP (51% vs 35% p=0,02; 44,86% vs 33,33%, p=0,03; 46,46% vs 33,08%, p=0,01 respectivamente) y a mayor probabilidad de CaP Gleason>7 (61,54% vs 37,5% p=0,02; 54,17% vs 34,12%, p=0,02; 54,35% vs 34,48% p=0,02 respectivamente). Además, la mediana de la ratio de TT/PSA fue significativamente menor en los pacientes con BxP positiva (p=0.022).

Conclusiones

el SM no se asoció con la probabilidad de tener CaP, pero sí con el CaP Gleason>7. Por otro lado, el SHT presentó un mayor porcentaje de CaP y una mayor presencia de CaP Gleason>7, al igual que los niveles bajos de TL y los niveles bajos de TB.

Palabras clave:
Cáncer de próstata
Síndrome de hipogonadismo tardío
Síndrome metabólico

Article

These are the options to access the full texts of the publication Actas Urológicas Españolas (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Actas Urológicas Españolas (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos